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Available online 12 January 2016Infectious and inﬂammatory diseases of the central nervous system are difﬁcult to identify early. Case deﬁnitions
for aseptic meningitis, encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM) are available,
but rarely put to use. The VACC-Tool (Vienna Vaccine Safety Initiative Automated Case Classiﬁcation-Tool) is a
mobile application enabling immediate case ascertainment based on consensus criteria at the point-of-care.
The VACC-Tool was validated in a quality management program in collaboration with the Robert-Koch-
Institute. Results were compared to ICD-10 coding and retrospective analysis of electronic health records using
the same case criteria. Of 68,921 patients attending the emergency room in 10/2010–06/2013, 11,575 were hos-
pitalized, with 521 eligible patients (mean age: 7.6 years) entering the quality management program. Using the
VACC-Tool at the point-of-care, 180/521 cases were classiﬁed successfully and 194/521 ruled out with certainty.
Of the 180 conﬁrmed cases, 116 had beenmissed by ICD-10 coding, 38misclassiﬁed. By retrospective application
of the same case criteria, 33 cases were missed. Encephalitis and ADEM cases were most likely missed or
misclassiﬁed. The VACC-Tool enables physicians to ask the right questions at the right time, thereby classifying
cases consistently and accurately, facilitating translational research. Future applications will alert physicians
when additional diagnostic procedures are required.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Data standards1. Introduction
Patients with acute infections of the central nervous system (CNS) or
post-infectious neuroinﬂammatory disease may present with a variety
of clinical signs and symptoms, which are often subtle or inconsistent
(Granerod et al., 2010; Koelman and Mateen, 2015). This poses a major
challenge in clinical practice, translational medicine, clinical trials, and
surveillance settings. Actual case numbers may be underestimated
delaying the detection of disease outbreaks and important safety signals
(Zwaan et al., 2010; Kelly et al., 2013;Gundlapalli et al., 2007). The timely
and accurate classiﬁcation of clinical cases constitutes an important pre-
requisite for precision medicine and timely access to therapy
(Gundlapalli et al., 2007; Hughes and Jackson, 2012; Duffy, 2015). The
ability to gain access to accurate clinical data in real-time will enablearité University Medical Center
. This is an open access article underhealthcare providers and public health stakeholders to overcome bar-
riers to therapeutic and diagnostic innovation (Duffy, 2015).
ADEM acute disseminated encephalomyelitis
VACC-Tool Vienna Vaccine Safety Initiative Automated Case Classiﬁca-
tion Tool
CNS Central nervous system
ICD International Catalog of Diseases
EHR electronic health records
QM quality management
IRB International review board
CDISC Clinical data interchange standards consortium
FDA Food and drug administration
PPA positive percent agreement
NPA negative percent agreement
ORA overall rate of agreement
KL Kullback Leibler
VAERS Vaccine adverse event reporting system
For billing purposes and in routine care, ICD-codes (International
Catalog of Diseases) are commonly used. ICD-codes do not distinguishthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
192 P. Obermeier et al. / EBioMedicine 4 (2016) 191–196between symptoms and diagnosis and are of limited value for systemat-
ic epidemiological research (St Germaine-Smith et al., 2012). For exam-
ple, the same case of aseptic meningitis can be coded as either
‘headache’ or ‘meningitis’.
ICD coding may thus result in considerable inconsistencies across
sites, which can only be avoided if pre-deﬁned case criteria are imple-
mented universally (Zwaan et al., 2010; Gundlapalli et al., 2007; St
Germaine-Smith et al., 2012; Horwitz and Yu, 1984; Rath et al., 2010;
Prins et al., 2002). Standardized case criteria are particularly important
as they have been developed for several complex neurological/autoim-
mune diseases, including aseptic meningitis, encephalitis, myelitis, and
acute disseminated encephalomyelitis (ADEM) (Tapiainen et al., 2007;
Sejvar et al., 2007). The application of these case criteria to electronic
health records (EHR) has been shown to provide reproducible and con-
sistent datasets aswell as signiﬁcant advantage over ICD-codes assigned
in routine care (Zwaan et al., 2010; Muehlhans et al., 2012; Lankinen
et al., 2004).
The same proof-of-concept study however, revealed that the retro-
spective application of standardized case criteria will result in a certain
amount of missing data and indeterminate results with regard to the
case deﬁnitions. This was the case whenever critical data that would
be required for the case deﬁnition, had not been documented in the
EHR (Rath et al., 2010). In other words, if a speciﬁc symptom such as
‘headache’ was not mentioned in the EHR, it will remain unclear to
the assessor whether the patient did not have any headaches to begin
with, or whether this question had not been raised during the physician
encounter (Horwitz and Yu, 1984).
This observation lead to the recommendation that standardized case
criteria should be implemented immediately at the point-of-care, when
the patient is still accessible and all pertinent data can be obtained (Rath
et al., 2010).
This translational research project aimed to evaluatewhether imme-
diate data collection with the use of innovative mobile applications
might enable the physician to ask the right questions at the right time,
thereby ensuring that all relevant information is collected at the
point-of-care. This would increase the yield of cases that can either be
classiﬁed and conﬁrmed, or ruled out with certainty.
2. Methods
This study builds on a previous proof-of-concept study performed
at a pediatric hospital in Switzerland, where standardized case
criteria for aseptic meningitis, encephalitis, myelitis, and ADEM
were applied retrospectively to hospital discharge summaries
(Rath et al., 2010).
Now, the same four consensus case deﬁnitions (Tapiainen et al.,
2007; Sejvar et al., 2007) were integrated a web-user interface (elec-
tronic clinical report form, CRF) as well as into a mobile application
for the standardized case ascertainment at the point-of-care: the
VACC-Tool (Vienna Vaccine Safety Initiative Automated Case Classi-
ﬁcation Tool, www.vi-vi.org). This innovative mobile application fa-
cilitating reliable case ascertainments at the patient's bedside, was
designed based on the user-centered and solution-focused princi-
ples of Design Thinking (Seeber et al., 2015). The installation of the
VACC-Tool on an Android-based handheld device using Java as a
platform-independent programing language required approximate-
ly 5 min. For full transparency, audit trails and double data entry ver-
iﬁcation procedures were enabled, and data entry was restricted to
authorized personnel only. Following the instructions of the Tool,
anonymized datasets required for the respective case deﬁnitions
were collected within approximately 20 min at the point-of-care. A
dynamic adaptation system with subordinate questions linked to
previously provided clinical information contributed to time-
efﬁcient assessments using the VACC-Tool. Automated algorithms
compared the collected data with the criteria of published case deﬁ-
nitions for meningitis, encephalitis, myelitis, and ADEM (Tapiainenet al., 2007; Sejvar et al., 2007). Results were provided immediately
at the patient's bedside. In accordance with the published case deﬁ-
nitions, cases were classiﬁed into three distinct levels of diagnostic
certainty, with Level 1 being closest to gold standard, Levels 2 and
3 being less stringent but still evident. Level 4 represented a case
with insufﬁcient data, whereas Level 5 indicated a deﬁnitive “rule-
out” (Tapiainen et al., 2007; Sejvar et al., 2007). Data entered into
the VACC-Tool were fully compliant with standards issued by
CDISC, the Clinical Data Interchange Standards Consortium (www.
cdisc.org) (Souza et al., 2007). Mapping of all data elements to Clin-
ical Data Acquisition Standards Harmonization (CDASH), Study Data
Tabulation Model (SDTM) and the Biomedical Research Integrated
Domain Group (BRIDG) Model enable instant data read-outs and ex-
ports, including for the automated submission of reports to regulato-
ry authorities (Linder et al., 2010).
The VACC-Tool was available as a web user interface (eCRF) as well
as a mobile application and was validated in the context of a quality
management (QM) program at the Charité Department of Pediatrics
in collaboration with the Robert-Koch-Institute in Berlin, Germany. All
hospitalized children (0–18 years) with suspected CNS infection or in-
ﬂammation meeting pre-deﬁned QM entry criteria underwent stan-
dardized assessments by a speciﬁcally trained QM team using the
VACC-Tool (Karsch et al., 2015). The QM team did not interfere with
routine diagnostics or physician orders for laboratory or imaging stud-
ies. The QM program was approved by the Charité Institutional Review
Board (IRB) (EA2/161/11). Informed consent procedures were waived
by the IRB for the purpose of quality improvement. This work received
no outside funding.2.1. Retrospective Application of Pre-deﬁned Case Criteria
For comparison, the same 521 clinical cases were re-classiﬁed apply-
ing the exact same case criteria and algorithms, but now retrospectively
using routine EHR rather than queries raised by theQMstaff at the point-
of-care. As per consensus for algorithm-based datasets, any undocu-
mented clinical signs or symptoms were reported as ‘absent’. Data ab-
straction and double entry veriﬁcation were performed by speciﬁcally
trained data entry staff in compliance with Good Clinical Practice
guidelines.2.2. Validating a New Diagnostic Standard Against an Imperfect Reference
Standard
Statistical analysis was performed using SPSS 21.0 software. In the
absence of an accepted gold standard for the differential diagnosis of
aseptic meningitis, encephalitis, myelitis, and ADEM, analyses were
conducted according to Food and Drug Administration (FDA) guidelines
and suggested terminologies for the reporting of results from studies
evaluating diagnostic tests. Positive and negative percent agreement
(PPA, NPA) and overall rates of agreement (ORA) were calculated to
test a new diagnostic test against the imperfect reference standard
(Fig. 1) (Rath et al., 2010).
Cross tabulations were used to compare the retrospective and pro-
spective application of case criteria in the same cohort. The statistical
power describes the probability of identifying an actual difference
with the used statistical test. Following Chow et al. (2008), we calculat-
ed the power of our test to be larger than 0.99 with n = 521 and
alpha = 0.05 (Chow et al., 2008).
Kappa coefﬁcients were calculated to assess the coincidence of con-
cordant/discordant results. P-values of less than 0.05 were considered
statistically signiﬁcant. Reported results were calculated with 95% con-
ﬁdence intervals based on the total sample size of 521, with a point es-
timate of 0.5 corresponding to the point of largest variance within a
binomial distribution (Rath et al., 2010).
Fig. 1. Calculation of positive and negative percent agreement (PPA, NPA) and overall rates of agreement (ORA).
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ture Selection measure (Hall, 1998). This method identiﬁes the best set
of features based on the two criteria:
(1) Features are highly correlated with the class to predict
(2) Features are not correlated with each other
The algorithm accounts for missing values by distributing them
across other values in proportion to their frequency.
The Kullback-Leibler (KL)-divergencewas used tomeasure the rela-
tive distance of two probability distributions. The KL-divergence be-
tween two distributions P and Q is deﬁned as
KLðP;QÞ ¼∑x⋲XPðxÞ  log P ðxÞQ ðxÞ (Kullback, 1987).
The KL-method was chosen as it does not make any assumption
about the distribution of dependent variables. In particular, it does not
assume that the dependent variable is normally distributed within
each comparison group. By deﬁnition, the KL-divergence cannot be neg-
ative and increases if two distributions become more different from
each other (Kullback, 1987).3. Results
From 11/2010–06/2013, a total of 68,921 patients seen in the emer-
gency roomwere screened prospectively,with 11,575patients hospital-
ized at the Charité Department of Pediatrics and 521 patients (4.5%)
fulﬁlling QM entry criteria (Karsch et al., 2015), mean age: 7.6 years
(0.03; 18.03), gender: 51% male.
A ﬂow diagram illustrating the case selection process is shown in
Fig. 2.Fig. 2. Case selection process.3.1. Using the VACC-Tool at the Point-of-Care
Using the VACC-Tool at the point-of-care, 34.6% of patients (180/
521) were successfully classiﬁed as either ‘aseptic meningitis’, ‘enceph-
alitis’, or ‘ADEM’. None of the 521 cases fulﬁlled myelitis case criteria. Of
the 341 unclassiﬁed cases, 194 were ruled out with certainty (Fig. 3).
3.2. Comparison Between Retrospective and Prospective Case Classiﬁcation
Applying the same algorithms to EHR retrospectively, 33 cases
(6.38%, 33/521) would have been missed and 38 cases (7.3%, 38/521)
would have been misclassiﬁed. In contrast to use of the VACC-Tool at
the point-of-care, important clinical data were not available in the
EHR of 33 patients.
3.3. Comparison Between ICD-10 and VACC-Tool at the Point-of-Care
Comparison of ICD-10 codes with use of the VACC-Tool at the point-
of-care revealed that 22.3% of cases (116/521) fulﬁlled any of the four
case deﬁnitions, but were not coded as such. The most commonly
missed diagnosis by ICD coding was ADEM (89/116, 76.7%). Additional
38 caseswould have beenmisclassiﬁed (e.g. encephalitis falsely as asep-
tic meningitis).
3.4. Analysis of Diagnostic Accuracy With the VACC-Tool
As expected with a conﬁrmatory diagnostic tool, NPA were usually
higher than PPA, suggesting that speciﬁc disease entities can be ruled
out with high levels of certainty.
Discrepancies between prospective and retrospective case classiﬁca-
tion were highest for complex disease entities such as encephalitis and
ADEM. Kappa coefﬁcients for assessing coincidence of concordant/dis-
cordant results were almost perfect for aseptic meningitis, whereas
they were considerably lower for encephalitis and ADEM (Table 1).
3.5. Key Features of VACC-Tool Classiﬁcations at the Point-of-Care
KL-divergence analysis revealed that pleocytosis in the cerebrospi-
nal ﬂuid (KL 8.34), followed by negative gram stain (KL 4.75) and bacte-
rial culture results (KL 3.38) were critical for the classiﬁcation of aseptic
meningitis.
For ADEM and encephalitis, characteristic histological ﬁndings
yielded highest KL-values (7.6), simultaneously leading to classiﬁca-
tions with highest levels of evidence (‘Level 1’ of diagnostic certainty).
Second highest KL-values for ADEM and encephalitis were assigned to
clinical signs of cranial nerve deﬁcits (KL 0.88 and 0.68 respectively).
Unbiased feature selection results conﬁrmed the combination of
both, clinical and laboratory/neuroimaging data as ‘relevant’. Table 2
displays unbiased feature selection results for VACC-Tool classiﬁcations
including KL-divergences for key features (Kullback, 1987).
Fig. 3. Case classiﬁcation results for asepticmeningitis (ASM), encephalitis (ENC), and acute disseminated encephalomyelitis (ADEM) among the same clinical cases (N=521) applying a)
automated VACC-Tool classiﬁcation at the point-of-care versus b) retrospective case classiﬁcation using identical algorithms based on medical records.
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We report the successful implementation of an evidence-based eCRF
and mobile application for the automated case classiﬁcation of aseptic
meningitis, encephalitis, myelitis, and ADEM at the point-of-care. Use
of the VACC-Tool at the patient's bedside lead to signiﬁcantly enhanced
data quality compared to standard of care (ICD coding) or retrospective
data mining using identical algorithms. The VACC-Tool allows physi-
cians to acquire all clinical parameters that are necessary to fulﬁll the re-
spective case deﬁnitions, thus generating meta-analyzable, highly
standardized data for real-time surveillance and precision medicine.
Standardized case ascertainment based on pre-deﬁned case deﬁni-
tions has been shown to be reproducible and consistent (Rath et al.,
2010;Muehlhans et al., 2012). The retrospective classiﬁcation of clinical
cases however, is often challenged by missing data in medical records,
thus leading to unclassiﬁable and indeterminate results (Horwitz and
Yu, 1984; Rath et al., 2010). Undocumented signs and symptoms are
usually indistinguishable from absent signs or symptoms, unless the
physician decided to explicitly document pertinent negative values
(Horwitz and Yu, 1984). Lack of standardization and data granularity
are key challenges to data mining and other downstream applications
based on medical data generated in routine care. This may lead to un-
derestimation of actual case numbers, with signiﬁcant consequences
to infectious disease surveillance, public health, and pharmacovigilance
(Linder et al., 2010; Al-Tawﬁq et al., 2014). Real-time data capturing
based on pre-deﬁned case criteria on the other hand, may increase the
numbers of suspected cases while ruling out true negatives (Rath
et al., 2010). The reported validation study conﬁrmed that with consis-
tent use of case deﬁnitions at thepoint-of-care, the number of suspected
cases may increase compared to retrospective case classiﬁcation. With
the help of the VACC-Tool, complete clinical datasets were captured.Table 1
Comparison of VACC-Tool case classiﬁcation at the point-of-care (VACC) with retrospec-
tive case classiﬁcation (RETRO) based on the same algorithms with overall rates of agree-
ment (ORA), positive percent agreement (PPA), negative percent agreement (NPA), and
kappa scores (k) (N = 521).
Categories Aseptic meningitis Encephalitis ADEM
VACC+ 63 65 76
VACC− 458 456 445
RETRO+ 61 65 69
RETRO− 460 456 452
VACC+/RETRO+ 59 40 54
VACC+/RETRO− 4 25 22
VACC−/RETRO+ 2 25 15
VACC−/RETRO− 456 431 430
ORA [95% CI] 99% [95; 100] 90% [86; 94] 93% [89; 97]
PPA [95% CI] 97% [93; 100] 62% [58; 66] 78% [74; 82]
NPA [95% CI] 99% [95; 100] 95% [91; 99] 95% [91; 99]
κ 0.95⁎⁎⁎ 0.56⁎⁎⁎ 0.70⁎⁎⁎
⁎⁎⁎ p b 0.001.There is an inherent limitation to the design of an independent
validation study. The VACC-Tool assessments were performed indepen-
dently by QM staff, whereas any orders for laboratory or neuroimaging
procedures remainedwith the treating physician and the routine hospi-
tal workﬂow. The organizational structure allowed independent valida-
tion of the Tool, but with the limitation that treating physicians did not
receive any information about the results of theVACC-Tool classiﬁcation
or any additional tests that would have been required to complete the
diagnostic algorithm. To solve all suspected cases in the present
study, additional laboratory and neuroimaging/electrophysiology data
would have been required in 147 indeterminate cases. For example,
lumbar punctures and neuroimaging and/or EEG studies had not
been ordered in 37 suspected cases, rendering the classiﬁcation into
‘aseptic meningitis versus encephalitis’ impossible. This drawback will
be avoided with future use, when the VACC-Tool will be issuing digital
reminders in cases where pertinent laboratory, neuroimaging, or elec-
trophysiology studies are indicated according to the respective case
deﬁnition.
Another limitation of this proof-of-concept study is that the initial
VACC-Tool included only four case deﬁnitions. The limited range of al-
gorithms may have resulted in some effect modiﬁcation and ascertain-
ment bias in favor of the pre-deﬁned disease entities represented in
the VACC-Tool. An unbiased and conclusive differentiation of the four
disease entities from related disease entities such asGuillain-Barré-Syn-
drome or Multiple Sclerosis will require the inclusion of additional case
deﬁnitions into the VACC-Tool and the reﬁnement of any areas of over-
lap. With increasing complexity of case algorithms, the VACC-Tool will
provide a clear advantage for the automated discrimination of closely
related but complex disease entities while providing CDSIC-compliant
standardized data at the point-of-care.
During the development of the VACC-Tool andmultiple rounds of it-
erations, the direct feedback from clinicians was instrumental, as they
were able to test the Tool in their everyday workﬂow and in busy clin-
ical care settings. The key motivation for clinicians to use the VACC-
Tool is the ability to discriminate several, including complex neurologic
disease entities reliably and consistently. In difﬁcult cases, for example,
patients presenting with clinical symptoms consistent with both ADEM
and encephalitis, such cases were classiﬁed as belonging to a pre-
deﬁned are of overlap between ADEM and encephalitis (Level 3A), indi-
cating a need for further imaging or histopathological studies to differ-
entiate the two. Therefore, the VACC-Tool promotes timely diagnoses
while decreasing interrater variability but it also opens the possibility
to trigger important follow-up diagnostic procedures, if indicated.
Diagnostic algorithms require the uniform assignment of positive as
well as negative values to each variable. Bioinformaticians interested in
machine learning and advanced precisionmedicine analyseswill ask for
a clear discrimination between positive and pertinent negative values
for each variable. Use of the VACC-Tool at the point-of-care increased
the number of conclusively and consistently classiﬁed cases thereby de-
creasing the risk of missing data. Therefore, use of the VACC-Tool
Table 2
Feature selection results are displayed for VACC-Tool classiﬁcation of aseptic meningitis,
encephalitis, and ADEM. Dark gray background color indicates a positive correlation (i.e.
the presence of a symptom is important) between clinical sign/laboratoryﬁnding and case
classiﬁcationwhereas light gray background color indicates a negative correlation (i.e. the
absence of a symptom is important). Numbers are KL-divergences, indicating increasing
importance with increasing numerical values.
Bu
lg
in
g 
fo
nt
an
el
le
 
Re
du
ce
d 
le
ve
l o
f 
co
ns
ci
ou
sn
es
s 
Le
th
ar
gy
 
Cr
an
ia
l n
er
ve
  d
ef
ic
it
 
Fe
ve
r 
Se
ns
or
y 
ab
no
rm
al
it
ie
s 
Ce
re
be
lla
r 
de
fi
ci
ts
 
(e
.g
. d
ys
m
et
ri
a)
Fo
ca
l c
or
ti
ca
l s
ig
ns
 
(e
.g
. a
le
xi
a)
D
ec
re
as
ed
 d
ee
p 
te
nd
on
 r
ef
le
xe
s 
Be
ha
vi
or
al
 c
ha
ng
es
 
Pl
eo
cy
to
si
s 
in
 
ce
re
br
os
pi
na
l f
lu
id
 
G
ra
m
 s
ta
in
 
N
eu
ro
im
ag
in
g 
Aseptic 
meningitis 0.05 0.12 0.28 0.88  1.32   8.34 4.7 
Encephalitis 0.68 0.26 0.06 0.13 0.19   
ADEM 0.88 0.54 0.29 0.04 0.05 0.32   0.77
195P. Obermeier et al. / EBioMedicine 4 (2016) 191–196facilitated the downstream application of unbiased feature selection
and machine learning algorithms to the clinical dataset. Feature selec-
tion analysis also conﬁrmed that the case classiﬁcations could have
been 100% complete if additional laboratory, neuroimaging, and electro-
physiology studies had been obtained if required according to the re-
spective consensus case deﬁnition. White cell counts, culture results,
and gram stains from cerebrospinal ﬂuid for example, are crucial when-
ever a clinical suspicion of aseptic meningitis or encephalitis is raised.
When such pertinent laboratory data are lacking, the number of inde-
terminate cases will increase.
The agreement between retrospective and prospective case classiﬁ-
cation was almost perfect for aseptic meningitis. This means that the
physician assessment in routine care was not too different from the re-
sults of the VACC Tool. In cases of ADEM or encephalitis however, rates
of agreement were lower, which may be attributed to the imperfection
of the reference standard (retrospective use of case criteria based on in-
complete datasets in health records). In other words, themore complex
the disease entity and the attribution of diagnoses in routine care, the
greater the added value of using the VACC-Tool.
In the future, the VACC-Tool will include a reminder-function
assisting the clinician to obtain laboratory, neuroimaging or electro-
physiology studies, if necessary.
The potential for quality improvement through mobile health tools
is evident: The physician will be enabled to ask the right questions at
the right time, thereby achieving greater data granularity and accuracy.
This may contribute to timely diagnoses and ultimately, improved pa-
tient satisfaction with the physician encounter (Lin et al., 2001). If stan-
dards are integrated effectively into the clinical workﬂow, for example
through mobile devices or pop-up windows in EHR, physicians will be
enabled to generate complete datasets that are compatible with
datasets obtained by their peers (Linder et al., 2010; Dal Pan, 2010).
For maximum data interoperability across sites, the VACC-Tool was de-
veloped in full compliance with HIPAA (Health Insurance Portability
and Accountability Act) privacy rules and CDISC data standards (Souza
et al., 2007). Consistency across sites is particularly important in
pharmacovigilance settings, where the ability to prove the absence of
adverse events provides the greatest challenge (Linder et al., 2010;
Oubari et al., 2015).
Automated case classiﬁcation may be of great value to disease sur-
veillance as well as vaccine and drug pharmacovigilance. If all relevant
questions are answered in real-time, i.e. at the point-of-care, the de-
nominator of eligible cases will be known immediately. The VACC-
Tool was speciﬁcally designed to enable precision medicine as it helps
to identify small subpopulations of patients, who may be at risk for ad-
verse events following immunization or rare disease presentations fol-
lowing infectious and other autoimmune triggers. Only when these
patients are diagnosed at the point-of-care, can biomarker studies andother subsequent studies be performed in a consistent manner. Use of
the VACC-Tool will generate well-deﬁned clinical datasets as they will
be required for precision medicine approaches and new, evidence-
based strategies to improve medical care for highly vulnerable patient
populations (Duffy, 2015; Jaffe, 2015).
Downstream applications may include additional algorithms for
causality assessments following successful case ascertainment. This
may help the clinician for example, to discriminate whether a speciﬁc
adverse event was triggered by ‘natural’ infection, vaccine or drug ad-
ministration, autoimmune disease, or other causes. The timely paper-
free transmission of unbiased safety data to health authorities repre-
sents one potential application of the VACC-Tool (Linder et al., 2010;
Al-Tawﬁq et al., 2014). To date, vaccine safety monitoring relies on pas-
sive surveillance systems such as VAERS (Vaccine Adverse Event
Reporting System), large linked databases, and ICD-codes, with signiﬁ-
cant limitations with respect to data standardization (Lankinen et al.,
2004; Baker et al., 2015).
Automated case classiﬁcation will contribute signiﬁcantly to the
timely diagnosis of important infectious diseases, which may be
under-recognized in routine care and therefore under-represented in
surveillance datasets (Kelly et al., 2013; Dale, 2003). The recent out-
break of enterovirus 71-associated CNS infections provides a practical
example, where automated case classiﬁcation in real-time might have
been useful to surveillance clinics and reference laboratories (Zander
et al., 2014). Further development and improvements of the VACC-
Tool could include the ability to ‘ﬂag’ any clinically suspect cases
prompting automated reporting of anonymized data signals. If integrat-
ed into the routine EHR workﬂow, the VACC-algorithms could be
programed to prompt consultations by infectious disease or infection
control specialists, thereby improving patient outcomes and quality of
care (Zwaan et al., 2010; Jaffe, 2015).
In a modiﬁed version adjusted to self-reported outcomes, the VACC-
Tool could also be used to strengthen the patient voice in disease sur-
veillance (Duffy, 2015). The language would need to be adjusted to ac-
commodate the direct reporting by laypersons willing to participate in
surveillance programs, thereby providing immediate feedback to
healthcare providers. For the long-termmonitoring of infectious disease
outcomes, patients could be encouraged to report any improvements
over time.
Finally, automated case classiﬁcation should be made available to
promote standardized, user-centered patient care in both, high- and
low-resource settings (Rath et al., 2010). The case criteria do accommo-
date their application diverse settings, as any speciﬁc case criteria may
be met with different levels of diagnostic certainty. If used widely, the
VACC-Tool will enable precision medicine based on unbiased assess-
ments in real-time, regardless of the setting.
5. Conclusion
Automated case classiﬁcation at the point-of-care will support the
physician to save time and improve patient care. The usual pitfalls of
underestimating or misclassifying infectious and neuroimmunological
diseases in routine care and ICD coding procedures can be avoided
effectively. Innovativemobile health tools will facilitate the timely iden-
tiﬁcation of relevant clinical cases at the point-of-care, including
neuroinfectious diseases as well as rare, neuroinﬂammatory adverse
events. Future studies will explore the integration of automated case
classiﬁcation systems into thebusyhospitalworkﬂow, facilitating trans-
lational research, surveillance systems, and the reporting of CDISC-
compliant anonymized meta-data to health authorities.
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